Hydroxychloroquine Market, By Disease Indication, By Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Hydroxychlorquine has exhibits the potential invitro activity against viruses including influenza, malaria, coronavirus, and many other diseases. The drug is under investigation to determine its efficacy for the treatment of novel coronavirus disease (COVID 19). According to the studies conducted in Wuhan, the body temperature recovery time and the cough remission time of coronavirus patients were significantly reduced with hydroxycloroquine and chloroquine treatment.

Despite the absence of strong evidence, the demand for hydroxychloroquine has spiked due to the coronavirus (COVID 19) outbreak. However, the doses of hydroxychloroquine need to be monitored, as its overdose can have dangerous side effects such as drowsiness, visual disturbances, cardiovascular collapse, convulsions, hypokalemia, rhythm, ventricular tachycardia, and ventricular fibrillation. This may lead to sudden respiratory and cardiac arrest, which can be fatal.

Market Dynamics

The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to evaluate the efficacy of hydroxchloroquine tablets for the treatment of patients with coronavirus disease (COVID 19) are expected to propel the market growth over the forecast period. For instance, on March 27, 2022, Rising Pharma Holdings Inc., a pharmaceutical company, entered into a collaborative agreement with the Division of Infectious Disease and International Medicine at the University of Minnesota, Department of Infectious Disease, to explore hydroxchloroquine as preventive treatment for coronavirus disease (COVID 19).

Key features of the study:

• This report provides in-depth analysis of the global hydroxchloroquine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global hydroxchloroquine market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, and Sun Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, disease indication up-gradation, market expansion, and marketing tactics
• The global hydroxchloroquine market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hydroxchloroquine market

Detailed Segmentation:

• Global Hydroxchloroquine Market, By Disease Indication:
  • Malaria
  • Coronavirus disease (COVID 19)
  • Lupus Erythematosus
  • Rheumatoid Arthritis
• Global Hydroxchloroquine Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Hydroxchloroquine Market, By Region:
  • North America
    • By Disease Indication:
    • Malaria
    • Coronavirus disease (COVID 19)
    • Lupus Erythematosus
    • Rheumatoid Arthritis
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • U.S.
    • Canada
  • Latin America
    • By Disease Indication:
    • Malaria
    • Coronavirus disease (COVID 19)
    • Lupus Erythematosus
    • Rheumatoid Arthritis
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Disease Indication:
    • Malaria
    • Coronavirus disease (COVID 19)
    • Lupus Erythematosus
    • Rheumatoid Arthritis
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Disease Indication:
    • Malaria
    • Coronavirus disease (COVID 19)
    • Lupus Erythematosus
    • Rheumatoid Arthritis
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Disease Indication:
    • Malaria
    • Coronavirus disease (COVID 19)
    • Lupus Erythematosus
    • Rheumatoid Arthritis
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Disease Indication:
    • Malaria
    • Coronavirus disease (COVID 19)
    • Lupus Erythematosus
    • Rheumatoid Arthritis
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Sanofi S.A.*
    • Company Overview
    • Material Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Amneal Pharmaceuticals, Inc.
  • Laurus Labs Limited
  • Zydus Pharmaceuticals, Inc.
  • Prasco Laboratories
  • Dr. Reddy's Laboratories
  • Cadila Pharmaceuticals
  • Novartis International AG
  • Concordia Pharmaceuticals Inc.
  • Covis Pharmaceuticals, Inc.
  • Cardinal Health
  • Aphena Pharma Solutions Tennessee, Inc.
  • Mylan N.V.
  • McKesson Corporation
  • Teva Pharmaceutical Industries Ltd
  • Lupin Pharmaceutical
  • Sun Pharmaceutical Industries Ltd

"*" marked represents similar segmentation in other categories in the respective section.